Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 3/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17510189 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL3360183 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL30688845 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29531496 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL1374145 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| Hydrochloric Acid SCHEMBL11183447 | 0.99 | MMP2 (0.63) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29531290 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29689355 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29376846 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29539550 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678240-A2 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | Hangzhou Dac Biotech Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| EP-3319936-B1 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | HANGZHOU DAC BIOTECH CO LTD (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250270247-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-28 | — | — | US | claimed |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| CN-119857156-A | Antibody drug conjugates | 武田药品工业株式会社 | 2025-04-22 | — | — | CN | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119770674-A | Antibody drug conjugates | 武田药品工业株式会社 | 2025-04-08 | — | — | CN | claimed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | claimed |
| CN-119255824-A | Ligand-drug conjugates with improved pharmacokinetic and drug release profiles | 德比欧药物研究有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | claimed |
| CN-109414109-A | Method for sampling gums metabolin | 宝洁公司 | 2019-03-01 | — | — | CN | claimed |
| US-9964472-B2 | Methods for sampling gingival metabolites | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-08 | — | — | US | claimed |
| US-20180003598-A1 | METHODS FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY | 2018-01-04 | — | — | US | claimed |
| WO-2018005335-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY (US) | 2018-01-04 | — | — | WO | claimed |
| CN-107356756-A | A kind of fluorescence probe and its synthetic method and the application in circulating tumor cell detection | 广州医科大学附属第五医院 | 2017-11-17 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| EP-2185552-B1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | ARG2, OAT, PDF | MMP2 1296/4885MME 736/4885ITGB3 4531/4885 |
| US-20250270247-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | MMP2 4803/4885MME 3685/4885ITGB3 3509/4885 |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | MMP2 1828/4885MME 2501/4885ITGB3 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.